- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Jade Biosciences to Present New Preclinical Data on JADE101 at the 62nd European Renal Association Congress | 1 | GlobeNewswire (USA) | ||
| 14.05. | Jade Biosciences, Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| JADE BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 09.05. | Pre-market Movers: ZK International, Jade Biosciences, Twin Vee Powercats, Corvus Pharmaceuticals, Iovance Biotherapeutics | 870 | AFX News | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.35 A.M. ET).In the Green ZK International Group Co., Ltd. (ZKIN) is up over... ► Artikel lesen | |
| 05.05. | Stifel initiates Jade Biosciences stock with a Buy, $19 target | 2 | Investing.com | ||
| 02.05. | TD Cowen starts Jade Biosciences coverage with Buy rating | 5 | Investing.com | ||
| 01.05. | Jade Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 30.04. | RTW Biotech Opportunities' Jade Biosciences merges with Aerovate Therapeutics | 1 | QuotedData | ||
| 30.04. | RTW Biotech Opp. - Jade Biosciences merges with Aerovate Therapeutics | - | RNS | ||
| 25.04. | Aerovate Therapeutics, Inc. - 10-Q, Quarterly Report | 4 | SEC Filings | ||
| 21.04. | Aerovate Therapeutics Stockholders Approve Merger Proposal With Jade Biosciences | 2 | RTTNews | ||
| 21.04. | Aerovate Therapeutics approves reverse split ahead of Jade merger | 1 | Investing.com | ||
| 21.04. | Aerovate Therapeutics genehmigt Aktienzusammenlegung vor Fusion mit Jade | 13 | Investing.com Deutsch | ||
| 21.04. | Aerovate Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 21.04. | Aerovate Therapeutics Stockholders Approve Proposed Merger with Jade Biosciences and All Related Proposals | 186 | PR Newswire | -Aerovate Board of Directors approves 1-for-35 reverse stock split-
WALTHAM, Mass., April 21, 2025 /PRNewswire/ -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE)... ► Artikel lesen | |
| 09.04. | Aerovate Therapeutics announces $69.6 million special dividend | 2 | Investing.com | ||
| 09.04. | Aerovate Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Jade Biosciences | 131 | PR Newswire | Aggregate cash dividend of $69.6 million, or an estimated $2.40 per share
WALTHAM, Mass., April 9, 2025 /PRNewswire/ -- Aerovate Therapeutics, Inc. (Nasdaq:... ► Artikel lesen | |
| 07.04. | Aerovate Therapeutics signals cash dividend ahead of Jade merger | 1 | Investing.com | ||
| 07.04. | Aerovate Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.04. | Aerovate Therapeutics Announces Range of Expected Cash Dividend in Connection with the Proposed Merger with Jade Biosciences | 178 | PR Newswire | Cash dividend expected to be in the range of $67.6 - 69.6 million
WALTHAM, Mass., April 7, 2025 /PRNewswire/ -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE) ("Aerovate")... ► Artikel lesen | |
| 27.03. | Aerovate Therapeutics, Inc. - 10-K, Annual Report | 2 | SEC Filings |
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BB BIOTECH | 32,850 | +0,77 % | BB Biotech - Optimistic about biotech's long-term prospects | During 2024 and early this year, the biotech sector began to show signs of a structural recovery, supported by positive clinical data, regulatory approvals, lower interest rates, commercial execution... ► Artikel lesen | |
| QIAGEN | 40,060 | -0,55 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat das Kursziel für Qiagen von 47 auf 50 US-Dollar angehoben und die Einstufung auf "Buy" belassen. Analyst Jan Koch zog in seinem am Dienstag... ► Artikel lesen | |
| NOVAVAX | 6,520 | -0,20 % | Aktien New York: Rücksetzer nach US-Bonitätsabstufung verpufft | NEW YORK (dpa-AFX) - Die Abstufung der US-Kreditwürdigkeit durch Moody?s hat die Anleger in New York am Montag nicht lange beeindruckt. Benoit Anne, Anleiheexperte bei MFS Investment Management, verwies... ► Artikel lesen | |
| STRYKER | 337,40 | +0,12 % | Former Intuitive, Stryker VP joins Think Surgical as EVP to advance surgical robot tech | ||
| ILLUMINA | 72,45 | -0,10 % | Does Illumina (ILMN) Have Good Long-Term Growth Prospects? | ||
| CRISPR THERAPEUTICS | 36,800 | 0,00 % | AKTIONÄR-Depotwert CRISPR Therapeutics: Cathie Wood kauft erneut | Die Aktie des Gen-Schere-Spezialisten CRISPR Therapeutics kommt seit Monaten nicht von der Stelle. Das aktuelle Niveau hat nun aber Cathie Wood zum Kauf genutzt. Die für Donnerstag veröffentlichten... ► Artikel lesen | |
| AAP IMPLANTATE | 1,420 | +6,77 % | EQS-AFR: aap Implantate AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: aap Implantate AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
aap Implantate AG: Vorabbekanntmachung... ► Artikel lesen | |
| OCUGEN | 0,917 | -0,97 % | Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea | Upfront fees and near-term development milestone payments totaling up to $11 millionSales milestones of $150 million or more in first 10 years of commercializationRoyalties equaling 25% of net salesOcugen... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 0,465 | +0,48 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering | Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the pricing of an underwritten offering consisting of 12,235,000 shares of its common stock and pre-funded warrants... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 7,146 | +0,37 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | CAMBRIDGE, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies... ► Artikel lesen | |
| SCORPIUS | 0,050 | 0,00 % | Scorpius Holdings, Inc. - 8-K, Current Report | ||
| EDITAS MEDICINE | 1,681 | 0,00 % | Editas Medicine ändert Aktienplan und erhöht genehmigte Aktien | ||
| DEFENCE THERAPEUTICS | 0,524 | -0,38 % | Defence Therapeutics Inc.: Defence Therapeutics Opens U.S. Laboratory in Boston-Cambridge Biotech Hub | Montreal, Quebec--(Newsfile Corp. - June 2, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in advanced... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 9,668 | -0,17 % | BioCryst Pharmaceuticals, Inc.: BioCryst Achieves Reimbursement for ORLADEYO Across all Major European Countries | RESEARCH TRIANGLE PARK, N.C., June 06, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that, following a positive recommendation from the Zorginstituut Nederland... ► Artikel lesen | |
| KUROS BIOSCIENCES | 26,300 | -0,23 % | Kuros Biosciences AG: Kuros Biosciences to share latest MagnetOs market impact and strategic priorities at Capital Market Day in Zürich | Kuros Biosciences to share latest MagnetOs market impact and strategic priorities at Capital Markets Day in Zürich
Schlieren (Zürich), Switzerland, May 13, 2025 - Kuros Biosciences ("Kuros"... ► Artikel lesen |
Das Unternehmen JADE BIOSCIENCES INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,260 (+3,77 %) liegt der Kurs bei 7,150 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu JADE BIOSCIENCES INC finden Sie auf Wallstreet Online.